BioPharmSignal logoBioPharmSignal

Biotech News

Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsFinancing

$21 Million debt financing, convertible to ENLV ordinary shares at fixed $2.69175 per share, a 264% premium to the Nasdaq closing price on March 20, 2026, with a single institutional investor

The Company exercised an option to acquire additional 3,030,303,030 RAIN tokens at $0.0033 per token, a 62% discount to its closing price on March 22,...

Related news

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

ENLVEnlivex Therapeutics2026-05-27 13:00 EST

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

IMNNImunon2026-06-04 12:00 EST

IMUNON Announces Up to $10 Million Cash Financing

REPLReplimune Group2026-08-10 12:00 EST

Replimune Announces Pricing of $150 Million Underwritten Offering

ELTXElicio Therapeutics, Inc.2026-07-06 20:05 EST

Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering

HOWLWerewolf Therapeutics2026-08-21 12:00 EST

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

MDNAMedicenna Therapeutics Corp.2026-05-28 13:10 EST

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

ELTXElicio Therapeutics, Inc.2026-07-02 04:25 EST

Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering

CUECue Biopharma Inc2026-07-10 01:40 EST

Cue Biopharma Announces $50.0 Million Private Placement

BCTXBriaCell2026-06-02 20:05 EST

BriaCell Therapeutics Announces Closing of Offering

View all latest news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

Stock data

Close
1.47 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States